References
- Kanski JJ, Bowling B. Kanski’s Clinical Ophthalmology: A Systematic Approach. 8th ed. Saunders; 2015.
- Khairullah AR. A comprehensive review of toxoplasmosis: serious threat to human health. Open Public Health J. 2024;17(1).
- Park YH, Nam HW. Clinical features and treatment of ocular toxoplasmosis. Korean J Parasitol. 2013;51(4):393–399.
- Butler NJ. Ocular toxoplasmosis II: clinical features, pathology and management. Clin Exp Ophthalmol. 2013;41(1):95–108.
- Kalogeropoulos D. Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches. Int Ophthalmol. 2022;42(1):295–321.
- Miyagaki M. Ocular toxoplasmosis: advances in Toxoplasma gondii biology, clinical manifestations, diagnostics, and therapy. Pathogens. 2024;13(10):898.
- Sauer A. Toxoplasmose oculaire. J Fr Ophtalmol. 2024;47(10): 104334.
- Delair E. Clinical manifestations of ocular toxoplasmosis. Ocul Immunol Inflamm. 2011;19(2):91–102.
- Pleyer U. Ocular toxoplasmosis: recent aspects of pathophysiology and clinical implications. Ophthalmic Res. 2014;52(3):116–23.
- Black MW, Boothroyd JC. Lytic cycle of Toxoplasma gondii. Microbiol Mol Biol Rev. 2000;64(3):607–23.
- Vasconcelos-Santos DV. Ocular manifestations of systemic disease. Curr Opin Ophthalmol. 2012;23(6):543–50.
- Fabiani S. Ocular toxoplasmosis, an overview focusing on clinical aspects. Acta Trop. 2022;225:106180.
- Kantzanou M. Prevalence of ocular toxoplasmosis among people living with HIV: a systematic review and meta-analysis. Future Microbiol. 2024.
- Kalogeropoulos D. Pathophysiological aspects of ocular toxoplasmosis: host-parasite interactions. Ocul Immunol Inflamm. 2022;30(3):560–9.
- Casoy J. Effectiveness of treatments for ocular toxoplasmosis. Ocul Immunol Inflamm. 2020;28(2):249–55.
- Agencja Oceny Technologii Medycznych i Taryfikacji Wydział Oceny Technologii Medycznych. Daraprim (pirymetamina) we wskazaniach: toksoplazmoza wrodzona, toksoplazmoza oczna, toksoplazmoza ośrodkowego układu nerwowego w przebiegu zakażenia HIV [Daraprim (pyrimethamine) in indications: congenital toxoplasmosis, ocular toxoplasmosis, central nervous system toxoplasmosis in HIV infection].